Publications by authors named "Paul Handley"

Claim this Profile
S
Structural and conformational studies of the heparan sulfate mimetic PI-88.
Stefano Elli, Eduardo Stancanelli, Paul N Handley, Anthony Carroll, Elena Urso

Glycobiology· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors.
Edward Hammond, Nicole M Haynes, Carleen Cullinane, Todd V Brennan, Darryn Bampton, Paul Handley

J Immunother Cancer· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours.
Keith Dredge, Todd V Brennan, Edward Hammond, Jason D Lickliter, Liwen Lin, Paul Handley

Br J Cancer· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New structural insights into the oligosaccharide phosphate fraction of Pichia (Hansenula) holstii NRRL Y2448 phosphomannan.
Paul N Handley, Anthony Carroll, Vito Ferro

Carbohydr Res· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanisms of heparanase inhibition by the heparan sulfate mimetic PG545 and three structural analogues.
Edward Hammond, Paul Handley, Keith Dredge, Ian Bytheway

FEBS Open Bio· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of PG545: a highly potent and simultaneous inhibitor of angiogenesis, tumor growth, and metastasis.
Vito Ferro, Ligong Liu, Ken D Johnstone, Norbert Wimmer, Tomislav Karoli, Paul Handley

J Med Chem· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis